메뉴 건너뛰기




Volumn 2014, Issue , 2014, Pages

Lipid nanoparticles as carriers for RNAi against viral infections: Current status and future perspectives

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOLIPOSOME; LIPID; LIPID DRUG CONJUGATE; LIPOPLEX; LIPOSOME; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; RNA; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

EID: 84907462391     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/161794     Document Type: Review
Times cited : (57)

References (178)
  • 3
    • 0024988334 scopus 로고
    • Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
    • S. A. Rosenberg, P. Aebersold, K. Cornetta et al., "Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction," New England Journal of Medicine, vol. 323, no. 9, pp. 570-578, 1990.
    • (1990) New England Journal of Medicine , vol.323 , Issue.9 , pp. 570-578
    • Rosenberg, S.A.1    Aebersold, P.2    Cornetta, K.3
  • 4
    • 79751506542 scopus 로고    scopus 로고
    • Gene therapy finds its niche
    • C. Sheridan, "Gene therapy finds its niche," Nature Biotechnology, vol. 29, no. 2, pp. 121-128, 2011.
    • (2011) Nature Biotechnology , vol.29 , Issue.2 , pp. 121-128
    • Sheridan, C.1
  • 5
    • 84907460586 scopus 로고    scopus 로고
    • Clinical Trial site
    • The Journal of Gene Medicine Clinical Trial site, http://www.abedia.com/wiley/indications.php.
    • The Journal of Gene Medicine
  • 6
    • 0032545933 scopus 로고    scopus 로고
    • Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans
    • A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, "Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans," Nature, vol. 391, no. 6669, pp. 806-811, 1998.
    • (1998) Nature , vol.391 , Issue.6669 , pp. 806-811
    • Fire, A.1    Xu, S.2    Montgomery, M.K.3    Kostas, S.A.4    Driver, S.E.5    Mello, C.C.6
  • 7
    • 9644275599 scopus 로고    scopus 로고
    • Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis
    • B. Kim, Q. Tang, P. S. Biswas et al., "Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis," The American Journal of Pathology, vol. 165, no. 6, pp. 2177-2185, 2004.
    • (2004) The American Journal of Pathology , vol.165 , Issue.6 , pp. 2177-2185
    • Kim, B.1    Tang, Q.2    Biswas, P.S.3
  • 8
    • 78751693009 scopus 로고    scopus 로고
    • Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection
    • M. S. Weinberg and P. Arbuthnot, "Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection," Genome Medicine, vol. 2, no. 4, pp. 28-34, 2010.
    • (2010) Genome Medicine , vol.2 , Issue.4 , pp. 28-34
    • Weinberg, M.S.1    Arbuthnot, P.2
  • 9
    • 84867380325 scopus 로고    scopus 로고
    • Therapeutic potential of RNA interference: A new molecular approach to antiviral treatment for hepatitis C
    • M. Motavaf, S. Safari, and S. M. Alavian, "Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C," Journal of Viral Hepatitis, vol. 19, no. 11, pp. 757-765, 2012.
    • (2012) Journal of Viral Hepatitis , vol.19 , Issue.11 , pp. 757-765
    • Motavaf, M.1    Safari, S.2    Alavian, S.M.3
  • 10
    • 84861318527 scopus 로고    scopus 로고
    • RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions
    • E. Xiaofei, B. M. Stadler, M. Debatis, S. Wang, S. Lu, and T. F. Kowalik, "RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions," Journal of Virology, vol. 86, no. 10, pp. 5660-5673, 2012.
    • (2012) Journal of Virology , vol.86 , Issue.10 , pp. 5660-5673
    • Xiaofei, E.1    Stadler, B.M.2    Debatis, M.3    Wang, S.4    Lu, S.5    Kowalik, T.F.6
  • 13
    • 84880364434 scopus 로고    scopus 로고
    • Role and application of RNA interference in replication of influenza viruses
    • T. Betáková and P. Švancarová, "Role and application of RNA interference in replication of influenza viruses," Acta Virologica, vol. 57, no. 2, pp. 97-104, 2013.
    • (2013) Acta Virologica , vol.57 , Issue.2 , pp. 97-104
    • Betáková, T.1    Švancarová, P.2
  • 14
    • 21844473275 scopus 로고    scopus 로고
    • High-throughput RNAi screening "in vitro": From cell lines to primary cells
    • D. Ovcharenko, R. Jarvis, S. Hunicke-Smith, K. Kelnar, and D. Brown, "High-throughput RNAi screening "in vitro": from cell lines to primary cells," RNA, vol. 11, no. 6, pp. 985-993, 2005.
    • (2005) RNA , vol.11 , Issue.6 , pp. 985-993
    • Ovcharenko, D.1    Jarvis, R.2    Hunicke-Smith, S.3    Kelnar, K.4    Brown, D.5
  • 15
    • 77955432320 scopus 로고    scopus 로고
    • TRNALys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs
    • V. Dyer, A. Ely, K. Bloom, M. Weinberg, and P. Arbuthnot, "TRNALys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs," Biochemical and Biophysical Research Communications, vol. 398, no. 4, pp. 640-646, 2010.
    • (2010) Biochemical and Biophysical Research Communications , vol.398 , Issue.4 , pp. 640-646
    • Dyer, V.1    Ely, A.2    Bloom, K.3    Weinberg, M.4    Arbuthnot, P.5
  • 16
    • 84888201452 scopus 로고    scopus 로고
    • Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs
    • M. Machitani, F. Sakurai, K. Katayama et al., "Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs," Virus Research, vol. 178, no. 2, pp. 357-363, 2013.
    • (2013) Virus Research , vol.178 , Issue.2 , pp. 357-363
    • Machitani, M.1    Sakurai, F.2    Katayama, K.3
  • 17
    • 84864995694 scopus 로고    scopus 로고
    • Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells
    • T. I. Novobrantseva, A. Borodovsky, J. Wong et al., "Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells," Molecular Therapy-Nucleic Acids, vol. 1, article e4, 2012.
    • (2012) Molecular Therapy-Nucleic Acids , vol.1
    • Novobrantseva, T.I.1    Borodovsky, A.2    Wong, J.3
  • 18
    • 84865955791 scopus 로고    scopus 로고
    • Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier
    • H. Arima, A. Yoshimatsu, H. Ikeda et al., "Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier," Molecular Pharmaceutics, vol. 9, pp. 2591-2604, 2012.
    • (2012) Molecular Pharmaceutics , vol.9 , pp. 2591-2604
    • Arima, H.1    Yoshimatsu, A.2    Ikeda, H.3
  • 19
    • 39549117983 scopus 로고    scopus 로고
    • Delivery vehicles for small interfering RNA in vivo
    • A. R. de Fougerolles, "Delivery vehicles for small interfering RNA in vivo," Human Gene Therapy, vol. 19, no. 2, pp. 125-132, 2008.
    • (2008) Human Gene Therapy , vol.19 , Issue.2 , pp. 125-132
    • De Fougerolles, A.R.1
  • 21
    • 0035863097 scopus 로고    scopus 로고
    • RNA interference is mediated by 21- and 22-nucleotide RNAs
    • S. M. Elbashir, W. Lendeckel, and T. Tuschl, "RNA interference is mediated by 21- and 22-nucleotide RNAs," Genes and Development, vol. 15, no. 2, pp. 188-200, 2001.
    • (2001) Genes and Development , vol.15 , Issue.2 , pp. 188-200
    • Elbashir, S.M.1    Lendeckel, W.2    Tuschl, T.3
  • 22
    • 26944441255 scopus 로고    scopus 로고
    • Dicing and slicing: The core machinery of the RNA interference pathway
    • S. M. Hammond, "Dicing and slicing: the core machinery of the RNA interference pathway," FEBS Letters, vol. 579, no. 26, pp. 5822-5829, 2005.
    • (2005) FEBS Letters , vol.579 , Issue.26 , pp. 5822-5829
    • Hammond, S.M.1
  • 23
    • 77957820261 scopus 로고    scopus 로고
    • RNAi and small interfering RNAs in human disease therapeutic applications
    • M. R. Lares, J. J. Rossi, and D. L. Ouellet, "RNAi and small interfering RNAs in human disease therapeutic applications," Trends in Biotechnology, vol. 28, no. 11, pp. 570-579, 2010.
    • (2010) Trends in Biotechnology , vol.28 , Issue.11 , pp. 570-579
    • Lares, M.R.1    Rossi, J.J.2    Ouellet, D.L.3
  • 24
    • 77954073897 scopus 로고    scopus 로고
    • Short hairpin RNA (shRNA): Design, delivery, and assessment of gene knockdown
    • C. B. Moore, E. H. Guthrie, M. T. Huang, and D. J. Taxman, "Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown," Methods in Molecular Biology, vol. 629, pp. 141-158, 2010.
    • (2010) Methods in Molecular Biology , vol.629 , pp. 141-158
    • Moore, C.B.1    Guthrie, E.H.2    Huang, M.T.3    Taxman, D.J.4
  • 28
    • 33745583788 scopus 로고    scopus 로고
    • RNA interference-mediated prevention and therapy for hepatocellular carcinoma
    • P. R. Romano, D. E. McCallus, and C. J. Pachuk, "RNA interference-mediated prevention and therapy for hepatocellular carcinoma," Oncogene, vol. 25, no. 27, pp. 3857-3865, 2006.
    • (2006) Oncogene , vol.25 , Issue.27 , pp. 3857-3865
    • Romano, P.R.1    McCallus, D.E.2    Pachuk, C.J.3
  • 30
    • 33947385291 scopus 로고    scopus 로고
    • Suppression of microRNA-silencing pathway by HIV-1 during virus replication
    • R. Triboulet, B. Mari, Y.L. Lin et al., "Suppression of microRNA-silencing pathway by HIV-1 during virus replication," Science, vol. 315, no. 5818, pp. 1579-1582, 2007.
    • (2007) Science , vol.315 , Issue.5818 , pp. 1579-1582
    • Triboulet, R.1    Mari, B.2    Lin, Y.L.3
  • 31
    • 23944506289 scopus 로고    scopus 로고
    • RNA interference is an antiviral defence mechanism in Caenorhabditis elegans
    • C. Wilkins, R. Dishongh, S. C. Moore, M. A. Whitt, M. Chow, and K. Machaca, "RNA interference is an antiviral defence mechanism in Caenorhabditis elegans," Nature, vol. 436, no. 7053, pp. 1044-1047, 2005.
    • (2005) Nature , vol.436 , Issue.7053 , pp. 1044-1047
    • Wilkins, C.1    Dishongh, R.2    Moore, S.C.3    Whitt, M.A.4    Chow, M.5    Machaca, K.6
  • 32
    • 35349009932 scopus 로고    scopus 로고
    • Interferon modulation of cellular microRNAs as an antiviral mechanism
    • I. M. Pedersen, G. Cheng, S. Wieland et al., "Interferon modulation of cellular microRNAs as an antiviral mechanism," Nature, vol. 449, no. 7164, pp. 919-922, 2007.
    • (2007) Nature , vol.449 , Issue.7164 , pp. 919-922
    • Pedersen, I.M.1    Cheng, G.2    Wieland, S.3
  • 33
    • 35748948383 scopus 로고    scopus 로고
    • Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome
    • T. Watanabe, T. Umehara, F. Yasui et al., "Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome," Journal of Hepatology, vol. 47, no. 6, pp. 744-750, 2007.
    • (2007) Journal of Hepatology , vol.47 , Issue.6 , pp. 744-750
    • Watanabe, T.1    Umehara, T.2    Yasui, F.3
  • 34
    • 59349118475 scopus 로고    scopus 로고
    • Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes
    • S. I. Kim, D. Shin, H. Lee, B. Ahn, Y. Yoon, and M. Kim, "Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes," Journal of Hepatology, vol. 50, no. 3, pp. 479-488, 2009.
    • (2009) Journal of Hepatology , vol.50 , Issue.3 , pp. 479-488
    • Kim, S.I.1    Shin, D.2    Lee, H.3    Ahn, B.4    Yoon, Y.5    Kim, M.6
  • 35
    • 57049173352 scopus 로고    scopus 로고
    • Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice
    • H. Lee, S. I. Kim, D. Shin et al., "Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice," Biochemical and Biophysical Research Communications, vol. 378, no. 2, pp. 192-196, 2009.
    • (2009) Biochemical and Biophysical Research Communications , vol.378 , Issue.2 , pp. 192-196
    • Lee, H.1    Kim, S.I.2    Shin, D.3
  • 36
    • 84867068265 scopus 로고    scopus 로고
    • Inhibition of hepatitis C virus replication by intracellular delivery ofmultiple siRNAs by nanosomes
    • P. K. Chandra, A. K. Kundu, S. Hazari et al., "Inhibition of hepatitis C virus replication by intracellular delivery ofmultiple siRNAs by nanosomes," Molecular Therapy, vol. 20, no. 9, pp. 1724-1736, 2012.
    • (2012) Molecular Therapy , vol.20 , Issue.9 , pp. 1724-1736
    • Chandra, P.K.1    Kundu, A.K.2    Hazari, S.3
  • 37
    • 84890775092 scopus 로고    scopus 로고
    • Minimal-length synthetic shRNAs formulated with lipid nanoparticles are potent inhibitors of hepatitis C virus IRES-linked gene expression in mice
    • A. Dallas, H. Ilves, J. Shorenstein, A. Judge, R. Spitler, and C. Conta, "Minimal-length synthetic shRNAs formulated with lipid nanoparticles are potent inhibitors of hepatitis C virus IRES-linked gene expression in mice," Molecular Therapy - Nucleic Acids, vol. 2, p. e123, 2013.
    • (2013) Molecular Therapy - Nucleic Acids , vol.2 , pp. e123
    • Dallas, A.1    Ilves, H.2    Shorenstein, J.3    Judge, A.4    Spitler, R.5    Conta, C.6
  • 39
    • 77955434240 scopus 로고    scopus 로고
    • Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages
    • W. Yu, C. Liu, Y. Liu, N. Zhang, and W. Xu, "Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages," Pharmaceutical Research, vol. 27, no. 8, pp. 1584-1596, 2010.
    • (2010) Pharmaceutical Research , vol.27 , Issue.8 , pp. 1584-1596
    • Yu, W.1    Liu, C.2    Liu, Y.3    Zhang, N.4    Xu, W.5
  • 41
    • 77957925036 scopus 로고    scopus 로고
    • A status report on RNAi therapeutics
    • A. K. Vaishnaw, J. Gollob, C. Gamba-Vitalo et al., "A status report on RNAi therapeutics," Silence, vol. 1, no. 1, article 14, 2010.
    • (2010) Silence , vol.1 , Issue.1
    • Vaishnaw, A.K.1    Gollob, J.2    Gamba-Vitalo, C.3
  • 42
    • 77349116570 scopus 로고    scopus 로고
    • pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles
    • E. Vighi, B. Ruozi, M. Montanari, R. Battini, and E. Leo, "pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles," International Journal of Pharmaceutics, vol. 389, no. 1-2, pp. 254-261, 2010.
    • (2010) International Journal of Pharmaceutics , vol.389 , Issue.1-2 , pp. 254-261
    • Vighi, E.1    Ruozi, B.2    Montanari, M.3    Battini, R.4    Leo, E.5
  • 44
    • 2242472082 scopus 로고    scopus 로고
    • Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations
    • R. H. Müller, M. Radtke, and S. A. Wissing, "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations," Advanced Drug Delivery Reviews, vol. 54, supplement 1, pp. S131-S155, 2002.
    • (2002) Advanced Drug Delivery Reviews , vol.54 , pp. S131-S155
    • Müller, R.H.1    Radtke, M.2    Wissing, S.A.3
  • 47
    • 23444445660 scopus 로고    scopus 로고
    • Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
    • D. V. Morrissey, J. A. Lockridge, L. Shaw et al., "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs," Nature Biotechnology, vol. 23, no. 8, pp. 1002-1007, 2005.
    • (2005) Nature Biotechnology , vol.23 , Issue.8 , pp. 1002-1007
    • Morrissey, D.V.1    Lockridge, J.A.2    Shaw, L.3
  • 48
    • 34249279852 scopus 로고    scopus 로고
    • Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I
    • S. I. Kim, D. Shin, T. H. Choi et al., "Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I," Molecular Therapy, vol. 15, no. 6, pp. 1145-1152, 2007.
    • (2007) Molecular Therapy , vol.15 , Issue.6 , pp. 1145-1152
    • Kim, S.I.1    Shin, D.2    Choi, T.H.3
  • 49
    • 67249148563 scopus 로고    scopus 로고
    • Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles
    • S. Carmona, M. R. Jorgensen, S. Kolli et al., "Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles," Molecular Pharmaceutics, vol. 6, no. 3, pp. 706-717, 2009.
    • (2009) Molecular Pharmaceutics , vol.6 , Issue.3 , pp. 706-717
    • Carmona, S.1    Jorgensen, M.R.2    Kolli, S.3
  • 50
    • 77950368673 scopus 로고    scopus 로고
    • DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA
    • M. Mével, N. Kamaly, S. Carmona et al., "DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA," Journal of Controlled Release, vol. 143, no. 2, pp. 222-232, 2010.
    • (2010) Journal of Controlled Release , vol.143 , Issue.2 , pp. 222-232
    • Mével, M.1    Kamaly, N.2    Carmona, S.3
  • 51
    • 77956894762 scopus 로고    scopus 로고
    • Inhibition of hepatitis B virus replication "in vivo" using lipoplexes containing altritol-modified antiviral siRNAs
    • J. Hean, C. Crowther, A. Ely et al., "Inhibition of hepatitis B virus replication "in vivo" using lipoplexes containing altritol-modified antiviral siRNAs," Artificial DNA: PNA and XNA, vol. 1, no. 1, pp. 17-26, 2010.
    • (2010) Artificial DNA: PNA and XNA , vol.1 , Issue.1 , pp. 17-26
    • Hean, J.1    Crowther, C.2    Ely, A.3
  • 52
    • 84907474519 scopus 로고    scopus 로고
    • Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients
    • A. Simon, V. Karsten, J. Cehelsky et al., "Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients," European Respiratory Journal, vol. 40, p. 267s, 2012.
    • (2012) European Respiratory Journal , vol.40 , pp. 267s
    • Simon, A.1    Karsten, V.2    Cehelsky, J.3
  • 54
    • 84907460585 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled safety, anti-viral, proof of concept study of Miravirsen, an oligonucleotide targeting miR-122, in treatment-naïve patients with genotype 1 chronic HCV infection
    • Program Number: LB-6
    • H. L. Janssen, H. W. Reesink, S. Zeuzem et al., "Randomized, double-blind, placebo-controlled safety, anti-viral, proof of concept study of Miravirsen, an oligonucleotide targeting miR-122, in treatment-naïve patients with genotype 1 chronic HCV infection," in Proceedings of the Liver Meeting by the AASLD - (62nd Annual Meeting), Program Number: LB-6, 2011.
    • (2011) Proceedings of the Liver Meeting by the AASLD - (62nd Annual Meeting)
    • Janssen, H.L.1    Reesink, H.W.2    Zeuzem, S.3
  • 55
    • 84907460584 scopus 로고    scopus 로고
    • http://www.benitec.com/documents/140529HEPATITISCPATGCOMMENCEDFINAL.pdf.
  • 56
    • 84907460583 scopus 로고    scopus 로고
    • http://www.arrowheadresearch.com/press-releases/arrowhead-begins-dosing-phase-2a-trial-rnai-therapeutic-arc-520-chronic-hepatitis-b.
  • 57
    • 84907460582 scopus 로고    scopus 로고
    • 2014, http://www.benitec.com/documents/1311-Calimmune-Presn-to-SIS.pdf.
    • (2014)
  • 58
    • 84884773211 scopus 로고    scopus 로고
    • Advances in lipid nanoparticles for siRNA delivery
    • Y. C. Tam, S. Chen, and P. R. Cullis, "Advances in lipid nanoparticles for siRNA delivery," Pharmaceutics, vol. 5, no. 3, pp. 498-507, 2013.
    • (2013) Pharmaceutics , vol.5 , Issue.3 , pp. 498-507
    • Tam, Y.C.1    Chen, S.2    Cullis, P.R.3
  • 59
    • 78650336277 scopus 로고    scopus 로고
    • Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis b surface antigen for vaccination using subcutaneous route
    • H. Mishra, D. Mishra, P. K. Mishra, M. Nahar, V. Dubey, and N. K. Jain, "Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis b surface antigen for vaccination using subcutaneous route," Journal of Pharmacy and Pharmaceutical Sciences, vol. 13, no. 4, pp. 495-509, 2010.
    • (2010) Journal of Pharmacy and Pharmaceutical Sciences , vol.13 , Issue.4 , pp. 495-509
    • Mishra, H.1    Mishra, D.2    Mishra, P.K.3    Nahar, M.4    Dubey, V.5    Jain, N.K.6
  • 61
    • 80052137679 scopus 로고    scopus 로고
    • Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel antileishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations
    • D. Doroud, A. Vatanara, F. Zahedifard et al., "Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel antileishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.," Journal of Controlled Release, vol. 148, no. 1, pp. e105-e106, 2010.
    • (2010) Journal of Controlled Release , vol.148 , Issue.1 , pp. e105-e106
    • Doroud, D.1    Vatanara, A.2    Zahedifard, F.3
  • 62
    • 41649113541 scopus 로고    scopus 로고
    • Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems
    • L. Priano, D. Esposti, R. Esposti et al., "Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems," Journal of Nanoscience and Nanotechnology, vol. 7, no. 10, pp. 3596-3601, 2007.
    • (2007) Journal of Nanoscience and Nanotechnology , vol.7 , Issue.10 , pp. 3596-3601
    • Priano, L.1    Esposti, D.2    Esposti, R.3
  • 65
    • 57149108667 scopus 로고    scopus 로고
    • A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors
    • A. del Pozo-Rodríguez, S. Pujals, D. Delgado et al., "A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors," Journal of Controlled Release, vol. 133, no. 1, pp. 52-59, 2009.
    • (2009) Journal of Controlled Release , vol.133 , Issue.1 , pp. 52-59
    • Del Pozo-Rodríguez, A.1    Pujals, S.2    Delgado, D.3
  • 69
    • 72449143073 scopus 로고    scopus 로고
    • Solid lipid nanoparticles as potential tools for gene therapy: "In vivo" protein expression after intravenous administration
    • A. del Pozo-Rodríguez, D. Delgado, M. Á. Solinís et al., "Solid lipid nanoparticles as potential tools for gene therapy: "in vivo" protein expression after intravenous administration," International Journal of Pharmaceutics, vol. 385, no. 1-2, pp. 157-162, 2010.
    • (2010) International Journal of Pharmaceutics , vol.385 , Issue.1-2 , pp. 157-162
    • Del Pozo-Rodríguez, A.1    Delgado, D.2    Solinís, M.Á.3
  • 70
    • 84857040855 scopus 로고    scopus 로고
    • Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: "In vitro" characterization and "in vivo" transfection after intravenous administration to mice
    • D. Delgado, A. R. Gascón, A. del Pozo-Rodríguez et al., "Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: "in vitro" characterization and "in vivo" transfection after intravenous administration to mice," International Journal of Pharmaceutics, vol. 425, no. 1-2, pp. 35-43, 2012.
    • (2012) International Journal of Pharmaceutics , vol.425 , Issue.1-2 , pp. 35-43
    • Delgado, D.1    Gascón, A.R.2    Del Pozo-Rodríguez, A.3
  • 71
    • 84860112894 scopus 로고    scopus 로고
    • Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis
    • D. Delgado, A. del Pozo-Rodríguez, M. Á. Solinís et al., "Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis," Human Gene Therapy, vol. 23, no. 4, pp. 345-355, 2012.
    • (2012) Human Gene Therapy , vol.23 , Issue.4 , pp. 345-355
    • Delgado, D.1    Del Pozo-Rodríguez, A.2    Solinís, M.Á.3
  • 73
    • 67649188363 scopus 로고    scopus 로고
    • Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery
    • W. Yu, C. Liu, J. Ye, W. Zou, N. Zhang, and W. Xu, "Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery," Nanotechnology, vol. 20, no. 21, Article ID 215102, 2009.
    • (2009) Nanotechnology , vol.20 , Issue.21
    • Yu, W.1    Liu, C.2    Ye, J.3    Zou, W.4    Zhang, N.5    Xu, W.6
  • 76
    • 51049101925 scopus 로고    scopus 로고
    • Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA
    • H. R. Kim, I. K. Kim, K. H. Bae, S. H. Lee, Y. Lee, and T. G. Park, "Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA," Molecular Pharmaceutics, vol. 5, no. 4, pp. 622-631, 2008.
    • (2008) Molecular Pharmaceutics , vol.5 , Issue.4 , pp. 622-631
    • Kim, H.R.1    Kim, I.K.2    Bae, K.H.3    Lee, S.H.4    Lee, Y.5    Park, T.G.6
  • 77
    • 84555220669 scopus 로고    scopus 로고
    • In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles
    • J. Jin, K. H. Bae, H. Yang et al., "In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles," Bioconjugate Chemistry, vol. 22, no. 12, pp. 2568-2572, 2011.
    • (2011) Bioconjugate Chemistry , vol.22 , Issue.12 , pp. 2568-2572
    • Jin, J.1    Bae, K.H.2    Yang, H.3
  • 78
    • 33947711751 scopus 로고    scopus 로고
    • Employment of cationic solid-lipid nanoparticles as RNA carriers
    • G. Montana, M. L. Bondì, R. Carrotta et al., "Employment of cationic solid-lipid nanoparticles as RNA carriers," Bioconjugate Chemistry, vol. 18, no. 2, pp. 302-308, 2007.
    • (2007) Bioconjugate Chemistry , vol.18 , Issue.2 , pp. 302-308
    • Montana, G.1    Bondì, M.L.2    Carrotta, R.3
  • 79
    • 77951690744 scopus 로고    scopus 로고
    • Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic
    • A. Puri, K. Loomis, B. Smithet al., "Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic," Critical Reviews in Therapeutic Drug Carrier Systems, vol. 26, no. 6, pp. 523-580, 2009.
    • (2009) Critical Reviews in Therapeutic Drug Carrier Systems , vol.26 , Issue.6 , pp. 523-580
    • Puri, A.1    Loomis, K.2    Smith, B.3
  • 80
    • 84864243269 scopus 로고    scopus 로고
    • Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    • S. Das, W. K. Ng, and R. B. H. Tan, "Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?" European Journal of Pharmaceutical Sciences, vol. 47, no. 1, pp. 139-151, 2012.
    • (2012) European Journal of Pharmaceutical Sciences , vol.47 , Issue.1 , pp. 139-151
    • Das, S.1    Ng, W.K.2    Tan, R.B.H.3
  • 81
    • 84877356531 scopus 로고    scopus 로고
    • Nanostructured lipid carriers (NLCs) for drug delivery and targeting
    • C. L. Fang, S. A. Al-Suwayeh, and J. Y. Fang, "Nanostructured lipid carriers (NLCs) for drug delivery and targeting," Recent Patents on Nanotechnology, vol. 7, no. 1, pp. 41-55, 2013.
    • (2013) Recent Patents on Nanotechnology , vol.7 , Issue.1 , pp. 41-55
    • Fang, C.L.1    Al-Suwayeh, S.A.2    Fang, J.Y.3
  • 82
    • 84868353989 scopus 로고    scopus 로고
    • Nanostructured lipid carriers system: Recent advances in drug delivery
    • M. A. Iqbal, S. Md, J. K. Sahni, S. Baboota, S. Dang, and J. Ali, "Nanostructured lipid carriers system: recent advances in drug delivery," Journal of Drug Targeting, vol. 20, no. 10, pp. 813-830, 2012.
    • (2012) Journal of Drug Targeting , vol.20 , Issue.10 , pp. 813-830
    • Iqbal, M.A.1    Md, S.2    Sahni, J.K.3    Baboota, S.4    Dang, S.5    Ali, J.6
  • 83
    • 84893047439 scopus 로고    scopus 로고
    • Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution
    • A. Beloqui, M. Á. Solinís, A. Delgado, C. Evora, A. Isla, and A. Rodríguez-Gascón, "Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution," Journal of Microencapsulation, vol. 31, no. 1, pp. 1-8, 2014.
    • (2014) Journal of Microencapsulation , vol.31 , Issue.1 , pp. 1-8
    • Beloqui, A.1    Solinís, M.Á.2    Delgado, A.3    Evora, C.4    Isla, A.5    Rodríguez-Gascón, A.6
  • 84
    • 34447305482 scopus 로고    scopus 로고
    • Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) - Effects of formulation parameters on physicochemical stability
    • V. Teeranachaideekul, R. H. Müller, and V. B. Junyaprasert, "Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability," International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 198-206, 2007.
    • (2007) International Journal of Pharmaceutics , vol.340 , Issue.1-2 , pp. 198-206
    • Teeranachaideekul, V.1    Müller, R.H.2    Junyaprasert, V.B.3
  • 85
    • 16344363233 scopus 로고    scopus 로고
    • Nanostructured lipid carriers: A novel generation of solid lipid drug carriers
    • M. Radtke, E. B. Souto, and R. H. Müller, "Nanostructured lipid carriers: a novel generation of solid lipid drug carriers," Pharmaceutical Technology Europe, vol. 17, no. 4, pp. 45-50, 2005.
    • (2005) Pharmaceutical Technology Europe , vol.17 , Issue.4 , pp. 45-50
    • Radtke, M.1    Souto, E.B.2    Müller, R.H.3
  • 86
    • 54049119962 scopus 로고    scopus 로고
    • Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject
    • M. Joshi, S. Pathak, S. Sharma, and V. Patravale, "Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject," International Journal of Pharmaceutics, vol. 364, no. 1, pp. 119-126, 2008.
    • (2008) International Journal of Pharmaceutics , vol.364 , Issue.1 , pp. 119-126
    • Joshi, M.1    Pathak, S.2    Sharma, S.3    Patravale, V.4
  • 88
    • 77953913053 scopus 로고    scopus 로고
    • Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and "in vivo" anti-malarial activity
    • N. P. Aditya, S. Patankar, B. Madhusudhan, R. S. R. Murthy, and E. B. Souto, "Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: pharmacokinetics, toxicological and "in vivo" anti-malarial activity," European Journal of Pharmaceutical Sciences, vol. 40, no. 5, pp. 448-455, 2010.
    • (2010) European Journal of Pharmaceutical Sciences , vol.40 , Issue.5 , pp. 448-455
    • Aditya, N.P.1    Patankar, S.2    Madhusudhan, B.3    Murthy, R.S.R.4    Souto, E.B.5
  • 89
    • 80054882310 scopus 로고    scopus 로고
    • Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers
    • K. W. Kasongo, J. Pardeike, R. H. Müller, and R. B. Walker, "Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers," Journal of Pharmaceutical Sciences, vol. 100, no. 12, pp. 5185-5196, 2011.
    • (2011) Journal of Pharmaceutical Sciences , vol.100 , Issue.12 , pp. 5185-5196
    • Kasongo, K.W.1    Pardeike, J.2    Müller, R.H.3    Walker, R.B.4
  • 91
    • 84899561000 scopus 로고    scopus 로고
    • Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs
    • A. Beloqui, M. Á. Solinís, A. des Rieux, V. Préat, and A. Rodríguez-Gascón, "Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs," International Journal of Pharmaceutics, vol. 468, no. 1-2, pp. 105-111, 2014.
    • (2014) International Journal of Pharmaceutics , vol.468 , Issue.1-2 , pp. 105-111
    • Beloqui, A.1    Solinís, M.Á.2    Des Rieux, A.3    Préat, V.4    Rodríguez-Gascón, A.5
  • 92
    • 84892675615 scopus 로고    scopus 로고
    • Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
    • O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko, and T. Minko, "Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA," Journal of Controlled Release, vol. 71, no. 3, pp. 349-357, 2013.
    • (2013) Journal of Controlled Release , vol.71 , Issue.3 , pp. 349-357
    • Taratula, O.1    Kuzmov, A.2    Shah, M.3    Garbuzenko, O.B.4    Minko, T.5
  • 93
    • 84860990287 scopus 로고    scopus 로고
    • Lipid matrix-drug conjugates particles for controlled release of active ingredient
    • US
    • R. H. Müller and C. Olbrich, "Lipid matrix-drug conjugates particles for controlled release of active ingredient," US6770299, 2004.
    • (2004)
    • Müller, R.H.1    Olbrich, C.2
  • 94
    • 79957680018 scopus 로고    scopus 로고
    • Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate
    • R. Paliwal, S. Rai, and S. P. Vyas, "Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate," Journal of Biomedical Nanotechnology, vol. 7, no. 1, pp. 130-131, 2011.
    • (2011) Journal of Biomedical Nanotechnology , vol.7 , Issue.1 , pp. 130-131
    • Paliwal, R.1    Rai, S.2    Vyas, S.P.3
  • 95
    • 84865324418 scopus 로고    scopus 로고
    • Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: Development, characterization and in vitro cell line studies
    • P. Sharma, B. Dube, and K. Sawant, "Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: development, characterization and in vitro cell line studies," Journal of Biomedical Nanotechnology, vol. 8, no. 6, pp. 928-937, 2012.
    • (2012) Journal of Biomedical Nanotechnology , vol.8 , Issue.6 , pp. 928-937
    • Sharma, P.1    Dube, B.2    Sawant, K.3
  • 96
    • 0035994314 scopus 로고    scopus 로고
    • Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate
    • C. Olbrich, A. Gessner, O. Kayser, and R. H. Müller, "Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate," Journal of Drug Targeting, vol. 10, no. 5, pp. 387-396, 2002.
    • (2002) Journal of Drug Targeting , vol.10 , Issue.5 , pp. 387-396
    • Olbrich, C.1    Gessner, A.2    Kayser, O.3    Müller, R.H.4
  • 97
    • 2142812902 scopus 로고    scopus 로고
    • Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene - Cytotoxicity testing and mouse serum adsorption
    • C. Olbrich, A. Gessner, W. Schröder, O. Kayser, and R. H. Müller, "Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene - cytotoxicity testing and mouse serum adsorption," Journal of Controlled Release, vol. 96,no. 3, pp.425-435, 2004.
    • (2004) Journal of Controlled Release , vol.96 , Issue.3 , pp. 425-435
    • Olbrich, C.1    Gessner, A.2    Schröder, W.3    Kayser, O.4    Müller, R.H.5
  • 98
    • 84907464491 scopus 로고    scopus 로고
    • Recent advances in myelodysplasia: Update from 2011 ASH annual meeting
    • D. Liu, "Recent advances in myelodysplasia: update from 2011 ASH annual meeting," Journal of Hematology & Oncology, vol. 5, supplement 1, p. A4, 2012.
    • (2012) Journal of Hematology & Oncology , vol.5 , pp. A4
    • Liu, D.1
  • 99
    • 84884648001 scopus 로고    scopus 로고
    • Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: "Ex vivo" gut permeation studies
    • Y. R. Neupane, M. D. Sabir, N. Ahmad, M. Ali, and K. Kohli, "Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine : "ex vivo" gut permeation studies," Nanotechnology, vol. 24, no. 41, Article ID 415102, 2013.
    • (2013) Nanotechnology , vol.24 , Issue.41
    • Neupane, Y.R.1    Sabir, M.D.2    Ahmad, N.3    Ali, M.4    Kohli, K.5
  • 101
    • 0033998938 scopus 로고    scopus 로고
    • A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system
    • S. W. Yi, T. Y. Yune, T. W. Kim et al., "A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system," Pharmaceutical Research, vol. 17, no. 3, pp. 314-320, 2000.
    • (2000) Pharmaceutical Research , vol.17 , Issue.3 , pp. 314-320
    • Yi, S.W.1    Yune, T.Y.2    Kim, T.W.3
  • 102
    • 33645753059 scopus 로고    scopus 로고
    • In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector
    • H. S. Yoo, O. Mazda, H. Y. Lee et al., "In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector," Journal of Controlled Release, vol. 112, no. 1, pp. 139-144, 2006.
    • (2006) Journal of Controlled Release , vol.112 , Issue.1 , pp. 139-144
    • Yoo, H.S.1    Mazda, O.2    Lee, H.Y.3
  • 103
    • 77049101923 scopus 로고    scopus 로고
    • Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions
    • M. M. Kaneda, Y. Sasaki, G. M. Lanza, J. Milbrandt, and S. A. Wickline, "Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions," Biomaterials, vol. 31, no. 11, pp. 3079-3086, 2010.
    • (2010) Biomaterials , vol.31 , Issue.11 , pp. 3079-3086
    • Kaneda, M.M.1    Sasaki, Y.2    Lanza, G.M.3    Milbrandt, J.4    Wickline, S.A.5
  • 105
    • 84863488545 scopus 로고    scopus 로고
    • Therapeutic siRNA: Principles, challenges, and strategies
    • K. Gavrilov and W. M. Saltzman, "Therapeutic siRNA: principles, challenges, and strategies," Yale Journal of Biology and Medicine, vol. 85, no. 2, pp. 187-200, 2012.
    • (2012) Yale Journal of Biology and Medicine , vol.85 , Issue.2 , pp. 187-200
    • Gavrilov, K.1    Saltzman, W.M.2
  • 106
    • 23044506285 scopus 로고    scopus 로고
    • Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
    • C. N. Landen Jr., A. Chavez-Reyes, C. Bucana et al., "Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery," Cancer Research, vol. 65, no. 15, pp. 6910-6918, 2005.
    • (2005) Cancer Research , vol.65 , Issue.15 , pp. 6910-6918
    • Landen, C.N.1    Chavez-Reyes, A.2    Bucana, C.3
  • 107
    • 33646144003 scopus 로고    scopus 로고
    • siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene
    • C. Zhang, N. Tang, X. Liu, W. Liang, W. Xu, and V. P. Torchilin, "siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene," Journal of Controlled Release, vol. 112, no. 2, pp. 229-239, 2006.
    • (2006) Journal of Controlled Release , vol.112 , Issue.2 , pp. 229-239
    • Zhang, C.1    Tang, N.2    Liu, X.3    Liang, W.4    Xu, W.5    Torchilin, V.P.6
  • 108
    • 42749097321 scopus 로고    scopus 로고
    • In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier
    • S. M. Kwon, H. Y. Nam, T. Nam et al., "In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier," Journal of Controlled Release, vol. 128, no. 1, pp. 89-97, 2008.
    • (2008) Journal of Controlled Release , vol.128 , Issue.1 , pp. 89-97
    • Kwon, S.M.1    Nam, H.Y.2    Nam, T.3
  • 109
    • 4444365598 scopus 로고    scopus 로고
    • Dioleoyl phosphatidylethnolamine and PEG-lipid conjugates modify DNA delivery medicated by 1, 4-dihydropyridine amphiphiles
    • Z. Hyvönen, S. Rönkkö, M.R. Toppinen, I. Jääskeäinen, A. Plotniece, and A. Urtti, "Dioleoyl phosphatidylethnolamine and PEG-lipid conjugates modify DNA delivery medicated by 1, 4-dihydropyridine amphiphiles," Journal of Controlled Release, vol. 99, no. 1, pp. 177-190, 2004.
    • (2004) Journal of Controlled Release , vol.99 , Issue.1 , pp. 177-190
    • Hyvönen, Z.1    Rönkkö, S.2    Toppinen, M.R.3    Jääskeäinen, I.4    Plotniece, A.5    Urtti, A.6
  • 110
    • 84883192300 scopus 로고    scopus 로고
    • Comparison of anti-EGFR-Fab′ conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells
    • L. Deng, Y. Zhang, L. Ma et al., "Comparison of anti-EGFR-Fab′ conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells," International Journal of Nanomedicine, vol. 8, pp. 3271-3283, 2013.
    • (2013) International Journal of Nanomedicine , vol.8 , pp. 3271-3283
    • Deng, L.1    Zhang, Y.2    Ma, L.3
  • 111
    • 76349095131 scopus 로고    scopus 로고
    • RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice
    • S. Kim, D. Peer, P. Kumar et al., "RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice," Molecular Therapy, vol. 18, no. 2, pp. 370-376, 2010.
    • (2010) Molecular Therapy , vol.18 , Issue.2 , pp. 370-376
    • Kim, S.1    Peer, D.2    Kumar, P.3
  • 113
    • 78651410969 scopus 로고    scopus 로고
    • Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine
    • J.M. Luke, G. G. Simon, J. Söderholm et al., "Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine," Journal of Virology, vol. 85, no. 3, pp. 1370-1383, 2011.
    • (2011) Journal of Virology , vol.85 , Issue.3 , pp. 1370-1383
    • Luke, J.M.1    Simon, G.G.2    Söderholm, J.3
  • 115
    • 18344381087 scopus 로고    scopus 로고
    • Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes
    • H. J. Hnatyszyn, "Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes," Antiviral Therapy, vol. 10, no. 1, pp. 1-11, 2005.
    • (2005) Antiviral Therapy , vol.10 , Issue.1 , pp. 1-11
    • Hnatyszyn, H.J.1
  • 116
    • 84891832915 scopus 로고    scopus 로고
    • Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: A meta-analysis
    • C. Park, S. Jiang, and K. A. Lawson, "Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis," Journal of Clinical Pharmacy and Therapeutics, vol. 39, no. 1, pp. 14-24, 2014.
    • (2014) Journal of Clinical Pharmacy and Therapeutics , vol.39 , Issue.1 , pp. 14-24
    • Park, C.1    Jiang, S.2    Lawson, K.A.3
  • 117
    • 4143088066 scopus 로고    scopus 로고
    • Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome
    • Y. Takigawa, M. Nagano-Fujii, L. Deng et al., "Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome," Microbiology and Immunology, vol. 48, no. 8, pp. 591-598, 2004.
    • (2004) Microbiology and Immunology , vol.48 , Issue.8 , pp. 591-598
    • Takigawa, Y.1    Nagano-Fujii, M.2    Deng, L.3
  • 118
    • 21744462419 scopus 로고    scopus 로고
    • Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone
    • R. Prabhu, P. Vittal, Q. Yin et al., "Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone," Journal of Medical Virology, vol. 76, no. 4, pp. 511-519, 2005.
    • (2005) Journal of Medical Virology , vol.76 , Issue.4 , pp. 511-519
    • Prabhu, R.1    Vittal, P.2    Yin, Q.3
  • 119
    • 33750365012 scopus 로고    scopus 로고
    • Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model
    • M. Kim, D. Shin, S. I. Kim, and M. Park, "Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model," Virus Research, vol. 122, no. 1-2, pp. 1-10, 2006.
    • (2006) Virus Research , vol.122 , Issue.1-2 , pp. 1-10
    • Kim, M.1    Shin, D.2    Kim, S.I.3    Park, M.4
  • 120
    • 33845549221 scopus 로고    scopus 로고
    • Small interfering RNA targeted to stem-loop II of the 5′ untranslated region effectively inhibits expression of six HCV genotypes
    • R. Prabhu, R. F. Garry, and S. Dash, "Small interfering RNA targeted to stem-loop II of the 5′ untranslated region effectively inhibits expression of six HCV genotypes," Virology Journal, vol. 3, article 100, 2006.
    • (2006) Virology Journal , vol.3
    • Prabhu, R.1    Garry, R.F.2    Dash, S.3
  • 121
    • 10744230911 scopus 로고    scopus 로고
    • Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interferring RNAs
    • T. Yokota, N. Sakamoto, N. Enomoto et al., "Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interferring RNAs," EMBO Reports, vol. 4, no. 6, pp. 602-608, 2003.
    • (2003) EMBO Reports , vol.4 , Issue.6 , pp. 602-608
    • Yokota, T.1    Sakamoto, N.2    Enomoto, N.3
  • 122
    • 33846113804 scopus 로고    scopus 로고
    • Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect
    • T. Kanda, R. Steele, R. Ray, and R. B. Ray, "Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect," Journal of Virology, vol. 81, no. 2, pp. 669-676, 2007.
    • (2007) Journal of Virology , vol.81 , Issue.2 , pp. 669-676
    • Kanda, T.1    Steele, R.2    Ray, R.3    Ray, R.B.4
  • 124
    • 61549133939 scopus 로고    scopus 로고
    • Inhibitionof HCV replication by small interfering RNA
    • R. B. Ray and T. Kanda, "Inhibitionof HCV replication by small interfering RNA," Methods in Molecular Biology, vol. 510, pp. 251-262, 2009.
    • (2009) Methods in Molecular Biology , vol.510 , pp. 251-262
    • Ray, R.B.1    Kanda, T.2
  • 125
    • 23944482649 scopus 로고    scopus 로고
    • Challenges and successes in developing new therapies for hepatitis C
    • R. de Francesco and G. Migliaccio, "Challenges and successes in developing new therapies for hepatitis C," Nature, vol. 436, no. 7053, pp. 953-960, 2005.
    • (2005) Nature , vol.436 , Issue.7053 , pp. 953-960
    • De Francesco, R.1    Migliaccio, G.2
  • 127
    • 33748081146 scopus 로고    scopus 로고
    • Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes
    • S. D. Henry, P. van der Wegen, H. J. Metselaar, H. W. Tilanus, B. J. Scholte, and L. J. W. van der Laan, "Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes," Molecular Therapy, vol. 14, no. 4, pp. 485-493, 2006.
    • (2006) Molecular Therapy , vol.14 , Issue.4 , pp. 485-493
    • Henry, S.D.1    Van Der Wegen, P.2    Metselaar, H.J.3    Tilanus, H.W.4    Scholte, B.J.5    Van Der Laan, L.J.W.6
  • 129
    • 80055083415 scopus 로고    scopus 로고
    • Countering hepatitis B virus infection using RNAi: How far are we from the clinic?
    • D. Ivacik, A. Ely, and P. Arbuthnot, "Countering hepatitis B virus infection using RNAi: How far are we from the clinic?" Reviews in Medical Virology, vol. 21, no. 6, pp. 383-396, 2011.
    • (2011) Reviews in Medical Virology , vol.21 , Issue.6 , pp. 383-396
    • Ivacik, D.1    Ely, A.2    Arbuthnot, P.3
  • 132
    • 78650807161 scopus 로고    scopus 로고
    • Hepatitis B virus resistance to antiviral drugs: Where are we going?
    • F. Zoulim, "Hepatitis B virus resistance to antiviral drugs: where are we going?" Liver International, vol. 31, supplement 1, pp. 111-116, 2011.
    • (2011) Liver International , vol.31 , pp. 111-116
    • Zoulim, F.1
  • 133
    • 84855341575 scopus 로고    scopus 로고
    • Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice
    • W. Jiang, "Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice," Vaccine, vol. 30, no. 4, pp. 758-766, 2012.
    • (2012) Vaccine , vol.30 , Issue.4 , pp. 758-766
    • Jiang, W.1
  • 134
    • 84877026189 scopus 로고    scopus 로고
    • Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection
    • C. I. Wooddell, D. B. Rozema, M. Hossbach et al., "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," Molecular Therapy, vol. 21, no. 5, pp. 973-985, 2013.
    • (2013) Molecular Therapy , vol.21 , Issue.5 , pp. 973-985
    • Wooddell, C.I.1    Rozema, D.B.2    Hossbach, M.3
  • 135
    • 0037382795 scopus 로고    scopus 로고
    • Inhibition of hepatitis B virus expression and replication by RNA interference
    • A. Shlomai and Y. Shaul, "Inhibition of hepatitis B virus expression and replication by RNA interference," Hepatology, vol. 37, no. 4, pp. 764-770, 2003.
    • (2003) Hepatology , vol.37 , Issue.4 , pp. 764-770
    • Shlomai, A.1    Shaul, Y.2
  • 137
    • 30344453089 scopus 로고    scopus 로고
    • Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs
    • S. Carmona, A. Ely, C. Crowther et al., "Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs," Molecular Therapy, vol. 13, no. 2, pp. 411-421, 2006.
    • (2006) Molecular Therapy , vol.13 , Issue.2 , pp. 411-421
    • Carmona, S.1    Ely, A.2    Crowther, C.3
  • 138
    • 77952425411 scopus 로고    scopus 로고
    • Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites
    • D. Sun, C. Rösler, K. Kidd-Ljunggren, and M. Nassal, "Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites," Hepatology, vol. 52, no. 6, pp. 817-826, 2010.
    • (2010) Hepatology , vol.52 , Issue.6 , pp. 817-826
    • Sun, D.1    Rösler, C.2    Kidd-Ljunggren, K.3    Nassal, M.4
  • 139
    • 84862820756 scopus 로고    scopus 로고
    • Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA
    • F. He, E. Chen, L. Liu et al., "Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA," Liver International, vol. 32, no. 5, pp. 742-751, 2012.
    • (2012) Liver International , vol.32 , Issue.5 , pp. 742-751
    • He, F.1    Chen, E.2    Liu, L.3
  • 140
    • 84873533812 scopus 로고    scopus 로고
    • A simple and robust vector-based shRNA expression system used for RNA interference
    • X. J. Wang, Y. Li, H. Huang et al., "A simple and robust vector-based shRNA expression system used for RNA interference," PLoS ONE, vol. 8, no. 2, Article ID e56110, 2013.
    • (2013) PLoS ONE , vol.8 , Issue.2
    • Wang, X.J.1    Li, Y.2    Huang, H.3
  • 142
    • 22544447827 scopus 로고    scopus 로고
    • Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors
    • M. D. Moore, M. J. McGarvey, R. A. Russell, B. R. Cullen, and M. O. McClure, "Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors," Journal of Gene Medicine, vol. 7, no. 7, pp. 918-925, 2005.
    • (2005) Journal of Gene Medicine , vol.7 , Issue.7 , pp. 918-925
    • Moore, M.D.1    McGarvey, M.J.2    Russell, R.A.3    Cullen, B.R.4    McClure, M.O.5
  • 143
    • 22044452139 scopus 로고    scopus 로고
    • Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment
    • K. Wu, X. Zhang, J. Zhang et al., "Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment," Virus Research, vol. 112, no. 1-2, pp. 100-107, 2005.
    • (2005) Virus Research , vol.112 , Issue.1-2 , pp. 100-107
    • Wu, K.1    Zhang, X.2    Zhang, J.3
  • 144
    • 84885022653 scopus 로고    scopus 로고
    • Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2′-O-guanidinopropyl modified siRNAs
    • M.D. Marimani, A. Ely, M. C. R. Buff, S. Bernhardt, J.W. Engels, and P. Arbuthnot, "Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2′-O-guanidinopropyl modified siRNAs," Bioorganic and Medicinal Chemistry, vol. 21, no. 20, pp. 6145-6155, 2013.
    • (2013) Bioorganic and Medicinal Chemistry , vol.21 , Issue.20 , pp. 6145-6155
    • Marimani, M.D.1    Ely, A.2    Buff, M.C.R.3    Bernhardt, S.4    Engels, J.W.5    Arbuthnot, P.6
  • 145
    • 18944373779 scopus 로고    scopus 로고
    • Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression
    • E. Ambegia, S. Ansell, P. Cullis, J. Heyes, L. Palmer, and I. MacLachlan, "Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression," Biochimica et Biophysica Acta: Biomembranes, vol. 1669, no. 2, pp. 155-163, 2005.
    • (2005) Biochimica et Biophysica Acta: Biomembranes , vol.1669 , Issue.2 , pp. 155-163
    • Ambegia, E.1    Ansell, S.2    Cullis, P.3    Heyes, J.4    Palmer, L.5    MacLachlan, I.6
  • 146
  • 147
    • 0036256430 scopus 로고    scopus 로고
    • Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells
    • N. S. Lee, T. Dohjima, G. Bauer et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells," Nature Biotechnology, vol. 20, no. 5, pp. 500-505, 2002.
    • (2002) Nature Biotechnology , vol.20 , Issue.5 , pp. 500-505
    • Lee, N.S.1    Dohjima, T.2    Bauer, G.3
  • 148
    • 38349166714 scopus 로고    scopus 로고
    • Optimal design and validation of antiviral siRNA for targeting HIV-1
    • Y. Naito, K. Nohtomi, T. Onogi et al., "Optimal design and validation of antiviral siRNA for targeting HIV-1," Retrovirology, vol. 4, article 80, 2007.
    • (2007) Retrovirology , vol.4
    • Naito, Y.1    Nohtomi, K.2    Onogi, T.3
  • 149
    • 58149458865 scopus 로고    scopus 로고
    • Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model
    • et al.
    • O. ter Brake, N. Legrand, K. J. von Eije et al. et al., "Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model," Gene Therapy, vol. 16, no. 1, pp. 148-153, 2009.
    • (2009) Gene Therapy , vol.16 , Issue.1 , pp. 148-153
    • Ter Brake, O.1    Legrand, N.2    Von Eije, K.J.3
  • 151
    • 70349683000 scopus 로고    scopus 로고
    • Specific transduction of hiv-susceptible cells for CCR5 knockdown and resistance to HIV infection: A novel method for targeted gene therapy and intracellular immunization
    • J. S. Anderson, J. Walker, J. A. Nolta, and G. Bauer, "Specific transduction of hiv-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization," Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 2, pp. 152-161, 2009.
    • (2009) Journal of Acquired Immune Deficiency Syndromes , vol.52 , Issue.2 , pp. 152-161
    • Anderson, J.S.1    Walker, J.2    Nolta, J.A.3    Bauer, G.4
  • 152
    • 84875311939 scopus 로고    scopus 로고
    • Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors
    • F. Boutimah, J. J. M. Eekels, Y.P. Liu, and B. Berkhout, "Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors," Antiviral Research, vol. 98, no. 1, pp. 121-129, 2013.
    • (2013) Antiviral Research , vol.98 , Issue.1 , pp. 121-129
    • Boutimah, F.1    Eekels, J.J.M.2    Liu, Y.P.3    Berkhout, B.4
  • 153
    • 12144291445 scopus 로고    scopus 로고
    • Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
    • R. G. Amado, R. T. Mitsuyasu, J. D. Rosenblatt et al., "Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients," Human Gene Therapy, vol. 15, no. 3, pp. 251-262, 2004.
    • (2004) Human Gene Therapy , vol.15 , Issue.3 , pp. 251-262
    • Amado, R.G.1    Mitsuyasu, R.T.2    Rosenblatt, J.D.3
  • 155
    • 77955608799 scopus 로고    scopus 로고
    • + cells in patients undergoing transplantation for AIDS-related lymphoma
    • + cells in patients undergoing transplantation for AIDS-related lymphoma," Science Translational Medicine, vol. 2, no. 36, pp. 36-43, 2010.
    • (2010) Science Translational Medicine , vol.2 , Issue.36 , pp. 36-43
    • DiGiusto, D.L.1    Krishnan, A.2    Li, L.3
  • 156
    • 84856204035 scopus 로고    scopus 로고
    • RNA-based Gene therapy for the treatment and prevention of HIV: From bench to bedside
    • S. J. Zeller and P. Kumar, "RNA-based Gene therapy for the treatment and prevention of HIV: from bench to bedside," The Yale Journal of Biology and Medicine, vol. 84, no. 3, pp. 301-309, 2011.
    • (2011) The Yale Journal of Biology and Medicine , vol.84 , Issue.3 , pp. 301-309
    • Zeller, S.J.1    Kumar, P.2
  • 157
    • 2942639506 scopus 로고    scopus 로고
    • Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance
    • X. Lu, Q. Yu, G. K. Binder et al., "Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance," Journal of Virology, vol. 78, no. 13, pp. 7079-7088, 2004.
    • (2004) Journal of Virology , vol.78 , Issue.13 , pp. 7079-7088
    • Lu, X.1    Yu, Q.2    Binder, G.K.3
  • 158
    • 33751001588 scopus 로고    scopus 로고
    • Silencing of HIV-1 with RNA interference: A multiple shRNA approach
    • O. ter Brake, P. Konstantinova, M. Ceylan, and B. Berkhout, "Silencing of HIV-1 with RNA interference: a multiple shRNA approach," Molecular Therapy, vol. 14, no. 6, pp. 883-892, 2006.
    • (2006) Molecular Therapy , vol.14 , Issue.6 , pp. 883-892
    • Ter Brake, O.1    Konstantinova, P.2    Ceylan, M.3    Berkhout, B.4
  • 159
    • 49549117077 scopus 로고    scopus 로고
    • T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice
    • P. Kumar, H. Ban, S. Kim et al., "T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice," Cell, vol. 134, no. 4, pp. 577-586, 2008.
    • (2008) Cell , vol.134 , Issue.4 , pp. 577-586
    • Kumar, P.1    Ban, H.2    Kim, S.3
  • 160
    • 44349164025 scopus 로고    scopus 로고
    • Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron
    • Y. P. Liu, J. Haasnoot, O. ter Brake, B. Berkhout, and P. Konstantinova, "Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron," Nucleic Acids Research, vol. 36, no. 9, pp. 2811-2824, 2008.
    • (2008) Nucleic Acids Research , vol.36 , Issue.9 , pp. 2811-2824
    • Liu, Y.P.1    Haasnoot, J.2    Ter Brake, O.3    Berkhout, B.4    Konstantinova, P.5
  • 161
    • 34247638978 scopus 로고    scopus 로고
    • Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis
    • J. R. Greenland, R. Geiben, S. Ghosh, W. A. Pastor, and N. L. Letvin, "Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis," Journal of Immunology, vol. 178, no. 9, pp. 5652-5658, 2007.
    • (2007) Journal of Immunology , vol.178 , Issue.9 , pp. 5652-5658
    • Greenland, J.R.1    Geiben, R.2    Ghosh, S.3    Pastor, W.A.4    Letvin, N.L.5
  • 162
    • 79954492561 scopus 로고    scopus 로고
    • Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination
    • R. Geiben-Lynn, K. Frimpong-Boateng, and N. L. Letvin, "Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination," Clinical and Vaccine Immunology, vol. 18, no. 4, pp. 533-538, 2011.
    • (2011) Clinical and Vaccine Immunology , vol.18 , Issue.4 , pp. 533-538
    • Geiben-Lynn, R.1    Frimpong-Boateng, K.2    Letvin, N.L.3
  • 163
    • 79957905425 scopus 로고    scopus 로고
    • Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras
    • L. A. Wheeler, R. Trifonova, V. Vrbanac et al., "Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras," Journal of Clinical Investigation, vol. 121, no. 6, pp. 2401-2412, 2011.
    • (2011) Journal of Clinical Investigation , vol.121 , Issue.6 , pp. 2401-2412
    • Wheeler, L.A.1    Trifonova, R.2    Vrbanac, V.3
  • 164
    • 2942620224 scopus 로고    scopus 로고
    • Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles
    • Z. Cui, J. Patel, M. Tuzova et al., "Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles," Vaccine, vol. 22, no. 20, pp. 2631-2640, 2004.
    • (2004) Vaccine , vol.22 , Issue.20 , pp. 2631-2640
    • Cui, Z.1    Patel, J.2    Tuzova, M.3
  • 165
    • 33645231644 scopus 로고    scopus 로고
    • HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant
    • J. Patel, D. Galey, J. Jones et al., "HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant," Vaccine, vol. 24, no. 17, pp. 3564-3573, 2006.
    • (2006) Vaccine , vol.24 , Issue.17 , pp. 3564-3573
    • Patel, J.1    Galey, D.2    Jones, J.3
  • 166
    • 78751581822 scopus 로고    scopus 로고
    • Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
    • M. A. Arias, A. Loxley, C. Eatmon et al., "Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen," Vaccine, vol. 29, no. 6, pp. 1258-1269, 2011.
    • (2011) Vaccine , vol.29 , Issue.6 , pp. 1258-1269
    • Arias, M.A.1    Loxley, A.2    Eatmon, C.3
  • 167
    • 30144434185 scopus 로고    scopus 로고
    • An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
    • D. Palliser, D. Chowdhury, Q. Wang et al., "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," Nature, vol. 439, no. 7072, pp. 89-94, 2006.
    • (2006) Nature , vol.439 , Issue.7072 , pp. 89-94
    • Palliser, D.1    Chowdhury, D.2    Wang, Q.3
  • 168
    • 58249094519 scopus 로고    scopus 로고
    • Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene
    • Y. Wu, F. Navarro, A. Lal et al., "Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene," Cell Host and Microbe, vol. 5, no. 1, pp. 84-94, 2009.
    • (2009) Cell Host and Microbe , vol.5 , Issue.1 , pp. 84-94
    • Wu, Y.1    Navarro, F.2    Lal, A.3
  • 169
    • 33645720317 scopus 로고    scopus 로고
    • Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
    • T. W. Geisbert, L. E. Hensley, E. Kagan et al., "Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference," Journal of Infectious Diseases, vol. 193, no. 12, pp. 1650-1657, 2006.
    • (2006) Journal of Infectious Diseases , vol.193 , Issue.12 , pp. 1650-1657
    • Geisbert, T.W.1    Hensley, L.E.2    Kagan, E.3
  • 170
    • 77952680862 scopus 로고    scopus 로고
    • Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study
    • T. W. Geisbert, A. C. Lee, M. Robbins et al., "Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study," The Lancet, vol. 375, no. 9729, pp. 1896-1905, 2010.
    • (2010) The Lancet , vol.375 , Issue.9729 , pp. 1896-1905
    • Geisbert, T.W.1    Lee, A.C.2    Robbins, M.3
  • 171
    • 77953351006 scopus 로고    scopus 로고
    • RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo
    • X. Z. Chen, K. J. Zhu, Y. Xu et al., "RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo," Clinical and Experimental Dermatology, vol. 35, no. 5, pp. 509-515, 2010.
    • (2010) Clinical and Experimental Dermatology , vol.35 , Issue.5 , pp. 509-515
    • Chen, X.Z.1    Zhu, K.J.2    Xu, Y.3
  • 172
    • 84867212940 scopus 로고    scopus 로고
    • Small interfering RNAs targeting the rabies virus nucleoprotein gene
    • Y. J. Yang, P. S. Zhao, T. Zhang et al., "Small interfering RNAs targeting the rabies virus nucleoprotein gene," Virus Research, vol. 169, no. 1, pp. 169-174, 2012.
    • (2012) Virus Research , vol.169 , Issue.1 , pp. 169-174
    • Yang, Y.J.1    Zhao, P.S.2    Zhang, T.3
  • 173
    • 84898669965 scopus 로고    scopus 로고
    • Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection
    • K. Khantasup, P. Kopermsub, K. Chaichoun, and T. Dharakul, "Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection," Antimicrobial Agents and Chemotherapy, vol. 58, no. 5, pp. 2816-2824, 2014.
    • (2014) Antimicrobial Agents and Chemotherapy , vol.58 , Issue.5 , pp. 2816-2824
    • Khantasup, K.1    Kopermsub, P.2    Chaichoun, K.3    Dharakul, T.4
  • 175
    • 84866950355 scopus 로고    scopus 로고
    • RNA interference for viral infections
    • S. J. Blake, F. F. Bokhari, and N.A. McMillan, "RNA interference for viral infections," Current Drug Targets, vol. 13, no. 11, pp. 1411-1420, 2012.
    • (2012) Current Drug Targets , vol.13 , Issue.11 , pp. 1411-1420
    • Blake, S.J.1    Bokhari, F.F.2    McMillan, N.A.3
  • 177
    • 84886261520 scopus 로고    scopus 로고
    • Current prospects for RNA interference-based therapies and delivery materials for siRNA therapeutics
    • R. Kanasty, J. R. Dorkin, A. Vegas, and D. Anderson, "Current prospects for RNA interference-based therapies and delivery materials for siRNA therapeutics," Nature Materials, vol. 12, pp. 967-977, 2013.
    • (2013) Nature Materials , vol.12 , pp. 967-977
    • Kanasty, R.1    Dorkin, J.R.2    Vegas, A.3    Anderson, D.4
  • 178
    • 84907465231 scopus 로고    scopus 로고
    • A Phase I, first in human clinical trial of ARC-520, an siRNA-based therapeutic for the treatment of chronic hepatitis B virus infection, in normal healthy volunteers
    • HEP DART
    • T. Schluep, L. Kalinoski, C. Wooddell, D. Lewis, R. Gish, and J. Lickliter, "A Phase I, first in human clinical trial of ARC-520, an siRNA-based therapeutic for the treatment of chronic hepatitis B virus infection, in normal healthy volunteers," Global Antiviral Journal, vol. 9, suplement 2, p. 57, 2013, HEP DART.
    • (2013) Global Antiviral Journal , vol.9 , pp. 57
    • Schluep, T.1    Kalinoski, L.2    Wooddell, C.3    Lewis, D.4    Gish, R.5    Lickliter, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.